NICE recommends natalizumab as a new treatment for adults with highly active relapsing-remitting multiple sclerosis ...
Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...
The ratio between two signaling molecules may be a key marker of MS brain inflammation and help identify candidates for BTK ...
Annual out-of-pocket treatment costs for multiple sclerosis increased by 125% from 2002 to 2021 in the US, driven mainly by ...
NICE has recommended Tysabri and biosimilar Tyruko as an option for patients with highly active relapsing-remitting multiple ...
England's NICE is recommending natalizumab, sold as Tysabri and Tyruko, as an NHS-covered treatment option for people with ...
NICE has recommended natalizumab for adults with highly active RRMS, citing pregnancy suitability, biosimilar value and NHS ...
Share on Pinterest A recent study reports that starting treatment at the first signs of MS symptoms could help slow disease progression. Jennifer Blount/Getty Images A recent study finds getting ...
As the multiple sclerosis (MS) population ages, managing the condition can bring new challenges. For one woman, working closely with her doctor, exploring treatment options, and finding the right ...
Many people with multiple sclerosis struggle with balance and coordination, and this study uncovers a hidden reason why.
NICE has recommended the drug, natalizumab, as an option for adults with relapsing-remitting MS (RRMS) that remains highly active after a full course of at least one disease-modifying therapy, and for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback